- Home
- SCPH vs NBTX Comparison
SCPH vs NBTX Comparison
Compare SCPH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- NBTX
- Stock Information
- Founded
- SCPH 2013
- NBTX 2003
- Country
- SCPH United States
- NBTX France
- Employees
- SCPH N/A
- NBTX N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- NBTX Health Care
- Exchange
- SCPH Nasdaq
- NBTX Nasdaq
- Market Cap
- SCPH 179.6M
- NBTX 201.9M
- IPO Year
- SCPH 2017
- NBTX 2020
- Fundamental
- Price
- SCPH $3.24
- NBTX $3.25
- Analyst Decision
- SCPH Strong Buy
- NBTX Strong Buy
- Analyst Count
- SCPH 2
- NBTX 1
- Target Price
- SCPH $15.00
- NBTX $12.00
- AVG Volume (30 Days)
- SCPH 412.0K
- NBTX 42.0K
- Earning Date
- SCPH 03-12-2025
- NBTX 09-18-2024
- Dividend Yield
- SCPH N/A
- NBTX N/A
- EPS Growth
- SCPH N/A
- NBTX N/A
- EPS
- SCPH N/A
- NBTX N/A
- Revenue
- SCPH $30,278,000.00
- NBTX $45,220,186.00
- Revenue This Year
- SCPH $172.64
- NBTX N/A
- Revenue Next Year
- SCPH $131.43
- NBTX N/A
- P/E Ratio
- SCPH N/A
- NBTX N/A
- Revenue Growth
- SCPH 303.87
- NBTX 526.17
- 52 Week Low
- SCPH $3.08
- NBTX $2.76
- 52 Week High
- SCPH $6.54
- NBTX $8.43
- Technical
- Relative Strength Index (RSI)
- SCPH 40.08
- NBTX 56.43
- Support Level
- SCPH $3.27
- NBTX $2.85
- Resistance Level
- SCPH $3.59
- NBTX $3.07
- Average True Range (ATR)
- SCPH 0.20
- NBTX 0.16
- MACD
- SCPH -0.01
- NBTX 0.05
- Stochastic Oscillator
- SCPH 15.00
- NBTX 73.67
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.